Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW ORLEANS, June...
TRI
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney disease ZHUBEI...
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type...
AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster...
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully...